by GOAI

由GOAI生成

Share To

分享到

Evommune, a clinical-stage biotechnology company, has secured $125 million through a private placement financing. The announcement, made on February 13, 2026, outlines the company’s successful efforts to raise funds from a group of institutional and accredited investors. The proceeds will support the advancement of Evommune’s pipeline of innovative therapies targeting chronic inflammatory diseases..

临床阶段生物技术公司Evommune通过私人配售融资筹集了1.25亿美元。公司在2026年2月13日的公告中概述了其成功从一批机构和认可投资者处筹集资金的努力。所得款项将用于推动Evommune针对慢性炎症性疾病的创新疗法的研发进程。

The financing round included participation from both new and existing investors. According to the company, the funds will primarily be allocated toward ongoing clinical trials and research initiatives aimed at developing treatments for conditions with significant unmet medical needs. Evommune focuses on leveraging its proprietary technology platform to address chronic inflammation across multiple therapeutic areas.

本轮融资有新投资者和现有投资者参与。据该公司称，这笔资金将主要用于正在进行的临床试验和研究计划，旨在开发针对存在显著未满足医疗需求的疾病治疗方法。Evommune 专注于利用其专有技术平台，在多个治疗领域解决慢性炎症问题。

Further details regarding specific investors or terms of the transaction were not disclosed in the announcement..

公告中未披露有关具体投资者或交易条款的更多细节。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如有任何建议和反馈，请联系我们。

Date: February 13, 2026

日期：2026年2月13日

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 保留所有权利。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章